All-In-One Screener Dividend Income Portfolio Ben Graham Lost Formula Canadian Faster Growers CEO Buys CEO Buys after Price Drop > 20% Dividend Growth Portfolio Dividend Income Portfolio Fast Growers Hedge Fund Guru Top 10 Aggregated High Quality High Quality Low Capex w ROE ROC min High Quality & Low Capex High Yield Insider Buys Historical High Dividend Yields International Gurus' Top Holdings James Montier Short Screen Margin Decliners Mega Caps Peter Lynch & Warren Buffett Peter Lynch Growth w Lower Valuation Peter Lynch S&L Traded Below Book PFCF Screener Piotroski Score Screener Predictable Growth Companies Profitable predictable margin expanders Stocks Sold w less Cash Good Companies The Stalwarts
All-In-One Screener S&P 500 Map S&P 500 Bubble S&P 500 Aggregate Buffett-Munger Screener Industry Overview Undervalued Predictable Benjamin Graham Net-Net 52-week/3Y/5Y Lows 52-week/3Y/5Y Highs Magic Formula(Greenblatt) Dividend Stocks Peter Lynch Screen S&P500 Grid Predictable Companies Spin Off List Historical Low P/B List Historical Low P/S List High Short Interest Upcoming Special Dividends Delisted Stocks
Model PortfoliosPerformances Undervalued Predictable Buffett-Munger Low P/S Low P/B 52w Low Predictable Broadest Owned Most Weighted
Latest Guru Picks List of Gurus Real Time Picks Guru Portfolio Top 10 Holdings View Guru Bargains Hot Picks Aggregated Portfolio Consensus Picks ETFS Score Board Sector Picks International Picks Industry Trends Geographic Trend Options European Shorting
Buffett Indicator Industry Overview U.S. Treasury Yield Curve Shiller P/E Global Market Valuations Economic Data Shiller P/E by Sectors Buffett Assets Allocation GF Value for SP500 Index
The Dow Jones Industrial Average (DJIA) SP 500 Index Nasdaq Composite Index Gross Domestic Product (GDP) Shiller PE Ratio of Wilshire 5000 over GNP Civilian Unemployment Rate Russell 2000 Small Cap Price Index CBOE Volatility Index (VIX) Total Nonfarm Payrolls: All Employees More...
Biomarin Pharmaceutical Inc $ 90.22 0 (0%)
Warning! GuruFocus has detected 1 Severe warning sign with BMRN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Add to your portfolio
Current and historical daily P/E ratio for Biomarin Pharmaceutical Inc () from 1999 to Jan 17 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biomarin Pharmaceutical stock (BMRN) PE ratio as of Jan 17 2022 is 1127.75. More Details
Biomarin Pharmaceutical PE Ratio (TTM) Historical Data
View and export this data going back to 1999. Start your Free Trial
Biomarin Pharmaceutical PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Traded in other countries / regions
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.